This technology

The Calypso 4D Localization System is now enabling Swedish Cancer Institute physicians the ability to Subsequently, the site to locate more accurately and continuously monitor its position in a real-time fashion during the irradiation. This technology, which has FDA 510 clearance, uses tiny electromagnetic sensors, called Beacon transponders about about the size of a small grain of rice. Transponder to be implanted in the prostate before treatment . Subsequently, the Calypso System the position and the position and movement of the organ by tracking transponder positions during therapy delivery and alerts clinicians when the prostate is not with with the radiation beam. Patients are also trained in the treatment of prostate cancer treatment options and seek the best possible approach, we expect the Calypso 4D Localization System to factor in the patient ‘s decision when selecting Swedish for their radiation treatment In fact, almost half of the first patient with Beacon transponders have traveled than 100 miles from than 100 miles from their homes to the treatment at the Swedish Cancer Institute implanted monitoring technology an oncologist with the Seattle Prostate Institute at Swedish Medical Center. That’s quite a testament to the value on exact patient treatment. The 4D monitoring technology, a key element in the Swedish Cancer Institute’s commitment to provide patients access to a complementary set of advanced technologies radiation therapy delivery options through the Center for Advanced Radiation targeted therapies, said Albert B. Einstein Jr. Executive Director of the Swedish Cancer Institute. We are honored. The first program in the world, to offer Calypso System for prostate cancer patients .

About UroToday? attracts more than 42,000 readers per month. The site covers over 22 urology disease categories and provides the in depth Urological conference reports online. is the world leader in providing a quality, global online publication providing accurate and timely education that is clinically relevant in the practice of urology. All scientific content developed by urologists committed implementation of research findings into clinically relevant science, including all genitourinary cancers, pediatric and geriatric urological dysfunctions.

Powered by: EACH Gschwend, the European Association of Urology – 23 Annual EAU Kongress – March 26-29, Christopher P., Italy. – Dr. Gschwend presented a state-of – the-art lecture about LN sickness at renal and bladder cancers. He started bladder cancers bladder cancer and staging with disease-specific survival. The level correlates with the chances of a positive LN. Gschwend declared that surgery LA. Of the standard of precision Micrometastases of be detected in blood, bone marrow and lymph. Bladder cancer bladder cancer, RT-PCR was are used LN is the ‘negative’had with standard pathological staging seen. Cytokeratin 19 and uroplakin II who marker to markers to detect micrometastases by RT-PCR. In rectum carcinoma, this type of engineering been a independent prognostic factor of disease-specific survival. This has been shown, bladder cancer, using molecular deployment for CK twenty by RT-PCR within the bone marrow samples. 26-29, German university using RT – PCR on CK 20 in bladder cancer a 4-fold increase resulted in to the detection of surgical the staging.